Aegis Capital sees good things in Stemline Therapeutics' (STML +1.8%) future, noting that the company "appears to be exceptionally well-funded [and] should continue to attract interest based on the accelerated development pathway for its lead drug candidate, SL-401 " (I, II, III). The shares are reiterated at Buy and the price target is raised to $40 from $35.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs